[The role of low-dose pramipexole in the treatment of treatment-resistant bipolar depression: a case report].
Despite a wide range of various drugs, a significant proportion of depressed bipolar patients fail to respond to the treatment strategies. Novel theraupetics for bipolar depression are needed. Preliminary studies suggest that pramipexole a dopaminergic agent that has been used in the treatment of Parkinson's disease and restless leg syndrome may have antidepressant properties in unipolar and bipolar depressed patients as well as neurotrophic properties. The optimal antidepressant daily dose of pramipexole is not known. It has been suggested to be used between 0.125 to 9.0 mg/day. In double blind placebo controlled bipolar depression treatment studies, the average daily dose of pramipexole was 1.7 mg. Manic switches have been reported with depressive subjects and with subjects without any mental disorders. We report two cases of treatment resistant bipolar depression. Despite different treatment strategies and treatment adherence, the patients did not give optimal response to the treatments and continue to experience depressive relapses. They have been treated with low dose (0.5-0.75 mg/day) pramipexole augmentation successfully. The severity and the duration of the depressive episodes were decreased. No serious adverse event has been reported with pramipexole during the maintenance treatment.
Akdeniz
Fisun
F
fisunakdeniz@yahoo.com
Aldemir
Ebru
E
Vahip
Simavi
S
D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage*; D052160:Benzothiazoles / Q000008:administration & dosage*; D001714:Bipolar Disorder / Q000188:drug therapy*; D018491:Dopamine Agonists / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077487:Pramipexole; D016896:Treatment Outcome
D000928:Antidepressive Agents; D052160:Benzothiazoles; D018491:Dopamine Agonists; D000077487:Pramipexole